HomeTWST • NASDAQ
Follow
Twist Bioscience Corp
Previous close
$28.57
Day range
$28.03 - $29.04
Year range
$11.46 - $43.21
Market cap
1.64B USD
Avg Volume
721.30K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Top news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 71.50M | 31.81% |
Operating expense | 75.94M | 3.23% |
Net income | -43.01M | -2.83% |
Net profit margin | -60.15 | 21.98% |
Earnings per share | -0.75 | 7.89% |
EBITDA | -38.81M | 10.74% |
Effective tax rate | -0.28% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 311.14M | -29.08% |
Total assets | 732.82M | -19.47% |
Total liabilities | 142.77M | -12.75% |
Total equity | 590.04M | — |
Shares outstanding | 57.82M | — |
Price to book | 2.80 | — |
Return on assets | -15.56% | — |
Return on capital | -16.78% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | -43.01M | -2.83% |
Cash from operations | -22.97M | 57.51% |
Cash from investing | 4.16M | 159.75% |
Cash from financing | -1.47M | -272.91% |
Net change in cash | -20.16M | 67.03% |
Free cash flow | -10.93M | 81.28% |
About
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
The company was represented by Leproust at a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox.
In May 2021, Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design. The CAD will automate workflows to enable collaborative efforts critical for scale-up from designing plasmids to megabases across entire genomes. Wikipedia
Founded
2013
Website
Employees
919
